Search Results
Found 1 results
510(k) Data Aggregation
(122 days)
Cefaly Acute
Cefaly® Acute is indicated for the acute treatment of migraine with or without aura in patients 18 years of age or older.
The Cefaly® Acute device is a supraorbital transcutaneous electrical nerve stimulator device to be applied on the forehead. A self-adhesive electrode with 2 conductive zones is placed on the forehead. This double electrode is directly connected to the device. The Cefaly® Acute is operated by a rechargeable battery. A pressure on the single switch starts a program, which runs automatically for 60 minutes.
This document describes the Cefaly® Acute device and its substantial equivalence to a predicate device (Cefaly®). It includes a summary of a clinical trial used to support its safety and efficacy.
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state "acceptance criteria" for the device's performance in a table format with specific numerical targets. However, the primary outcome of the clinical study serves as the de-facto performance measure demonstrating efficacy. The performance of the Cefaly® Acute is compared against a sham group.
Acceptance Criteria (Implied) | Reported Device Performance (Cefaly® Acute) | Reported Device Performance (Sham Group) | Statistical Significance |
---|---|---|---|
Reduction in pain score from baseline to 1 hour | Mean change in VAS pain score: -3.46 ± 2.32 | Mean change in VAS pain score: -1.78 ± 1.89 | Statistically significant (p |
Ask a specific question about this device
Page 1 of 1